No Data
No Data
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals Positioned for Success With Promising Oral Therapy TERN-601 Amid Novo Nordisk's Setback
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Announces Target Price $14
Mizuho Securities Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)
No Data